Graft Versus Host Disease clinical trials at UCLA
6 in progress, 3 open to eligible people
Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
open to eligible people ages 12 years and up
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Los Angeles, California and other locations
Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
open to eligible people ages 18 years and up
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Los Angeles, California and other locations
PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease
open to eligible people ages 12 years and up
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Los Angeles, California and other locations
Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Sorry, in progress, not accepting new patients
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
Los Angeles, California and other locations
Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Sorry, accepting new patients by invitation only
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Los Angeles, California and other locations
Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Sorry, in progress, not accepting new patients
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Los Angeles, California and other locations
Our lead scientists for Graft Versus Host Disease research studies include Gary J. Schiller, MD Sven de Vos, MD, PhD Wanxing Chai-Ho, MD.
Last updated: